B. Hoepken

发表

Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol

W. Maksymowych, M. Rudwaleit, T. Kumke, 2021, Arthritis Research & Therapy.

The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW

F. Verbraak, J. Rosenbaum, I. E. van der Horst-Bruinsma, 2020, RMD Open.

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA

M. Dougados, D. M. van der Heijde, R. Landewé, 2017, Rheumatology.

Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol

D. M. van der Heijde, D. Heijde, A. Deodhar, 2013, Annals of the rheumatic diseases.

Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure

D. Gladman, D. M. van der Heijde, R. Landewé, 2015, RMD Open.

Effectiveness and Safety of Certolizumab Pegol in Axial Spondyloarthritis in a Real-World Setting in Greece: A Sub-Analysis of the Prospective Non-Interventional CIMAX Cohort Study

P. Sfikakis, T. Dimitroulas, A. Theodoridou, 2022, Mediterranean journal of rheumatology.

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis

D. M. van der Heijde, R. Landewé, D. Heijde, 2016, Arthritis care & research.

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis

A. Gottlieb, D. Gladman, D. M. van der Heijde, 2018, RMD Open.

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

D. M. van der Heijde, D. Heijde, A. Deodhar, 2013, Annals of the rheumatic diseases.

Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative Review

F. Verbraak, A. Deodhar, E. Favalli, 2022, Rheumatology and Therapy.

Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study

F. Verbraak, A. Deodhar, I. E. van der Horst-Bruinsma, 2021, Therapeutic advances in musculoskeletal disease.

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study

M. Dougados, J. Reveille, D. M. van der Heijde, 2013, Annals of the rheumatic diseases.

EFFECT OF CERTOLIZUMAB PEGOL ON SIGNS AND SYMPTOMS IN PATIENTS WITH PSORIATIC ARTHRITIS WITH OR WITHOUT PRIOR ANTI-TNF EXPOSURE : 24-WEEK RESULTS OF A PHASE III DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY

P. Mease, R. Fleischmann, D. Kielar, 2012 .

Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial

D. M. van der Heijde, R. Landewé, P. Machado, 2018, Annals of the rheumatic diseases.

Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study

J. Braun, X. Baraliakos, T. Nurminen, 2021, Rheumatology.

A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis

D. M. van der Heijde, R. Landewé, A. Deodhar, 2019, Arthritis & rheumatology.

Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial

M. Dougados, D. M. van der Heijde, R. Landewé, 2015, Arthritis & rheumatology.

Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe

N. Goodson, T. Witte, B. Frediani, 2020, Rheumatology.

Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE

M. Dougados, D. M. van der Heijde, R. Landewé, 2020, Rheumatology and Therapy.

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction

M. Dougados, D. M. van der Heijde, R. Landewé, 2020, Annals of the Rheumatic Diseases.

Validation of the Ankylosing Spondylitis Quality of Life assessment tool in patients with non-radiographic axial spondyloarthritis

J. Reveille, B. Hoepken, Daniel Serrano, 2020, Quality of Life Research.

Certolizumab Pegol Efficacy in Patients With Non‐Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C‐Reactive Protein Status: An Analysis From the C‐axSpAnd Study

A. Deodhar, L. Gensler, W. Maksymowych, 2022, ACR open rheumatology.

Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study

A. Deodhar, L. Gensler, W. Maksymowych, 2022, RMD Open.

Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis

D. M. van der Heijde, R. Landewé, P. Machado, 2017, RMD Open.

Ef fi cacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis : 24-week results of a double-blind randomised placebo-controlled Phase 3 study

M. Dougados, R. Landewé, D. Heijde, 2013 .

THU0201 Factors Associated with Structural Damage in the Spine, as Measured by X-ray, in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol Over 96 Weeks

D. M. van der Heijde, R. Landewé, J. Braun, 2015 .

P242 CZP improves work and household productivity and social participation over 1 year of treatment in patients with non-radiographic axSpA

R. Landewé, A. Deodhar, L. Gensler, 2020 .

Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial

A. Gottlieb, J. Walsh, P. Mease, 2018, Clinical Rheumatology.

210. Effect of Certolizumab Pegol Over 48 Weeks on Signs and Symptoms in Patients with Psoriatic Arthritis with and Without Prior Tumor Necrosis Factor Inhibitor Exposure

D. Gladman, D. Heijde, A. Deodhar, 2014 .

FRI0419 Effect of certolizumab pegol on inflammation of spine and sacroiliac joints in patients with axial spondyloarthritis: 12-week magnetic resonance imaging results of rapid-axspa study

D. M. van der Heijde, R. Landewé, A. Fichtner, 2013 .

A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis

D. M. van der Heijde, R. Landewé, A. Deodhar, 2019, Arthritis & rheumatology.

OP0077 Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Psoriatic Arthritis with and without Prior Anti-Tumor Necrosis Factor Exposure: 96-Week Outcomes from the Rapid-Psa Trial

D. Gladman, A. Deodhar, R. Fleischmann, 2014 .

Long-Term Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure.

D. Gladman, A. Deodhar, P. Mease, 2014 .